A Study to Assess the Safety and Tolerability of Anti-MIF Antibody in Subjects With Lupus Nephritis.

Trial Profile

A Study to Assess the Safety and Tolerability of Anti-MIF Antibody in Subjects With Lupus Nephritis.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 03 Jul 2015

At a glance

  • Drugs Imalumab (Primary)
  • Indications Lupus nephritis
  • Focus Adverse reactions
  • Sponsors Baxter Healthcare Corporation
  • Most Recent Events

    • 21 Mar 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 27 Mar 2012 Additional locations (Australia, Canada, Mexico and New Zealand) added as reported by ClinicalTrials.gov.
    • 06 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top